Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian Contraception Consensus (Part 3 of 4), Chapter 8: Progestin-Only Contraception. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC progestin contraception
Source-attributed clinical priorities
- Confirm pregnancy status and review breast cancer, liver disease, interacting medicines, bleeding concerns and adherence needs.
- Explain that missed-pill windows and backup instructions differ by progestogen product.
- Plan follow-up for troublesome bleeding, adverse effects or adherence and give emergency-contraception advice after incorrect use.
- Different progestogen-only pills have different missed-pill windows, so advice must match the exact product.
sources for this section:SOGC progestin contraception
Practical assessment and management workflow
1
Exclude pregnancy and review breast cancer, liver disease, unexplained bleeding and interacting medicines.
2
Discuss bleeding variability, daily timing, effectiveness and alternatives including longer-acting methods.
3
Explain product-specific start, backup and missed-dose instructions.
4
Review adherence, bleeding, pregnancy symptoms and any new contraindication.
sources for this section:SOGC progestin contraception
Safety, red flags and urgent escalation
- Severe abdominal pain with a positive pregnancy test requires ectopic assessment.
- Enzyme-inducing medicines may reduce effectiveness of some oral progestogen methods.
- Do not apply missed-pill instructions from one formulation to another.
sources for this section:SOGC progestin contraception
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC progestin contraception
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC progestin contraception
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaCanadian Contraception Consensus (Part 3 of 4), Chapter 8: Progestin-Only Contraceptionaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.